CN102805882B - Method for mixing soft tissue filling agent with anesthetic injecta before use - Google Patents
Method for mixing soft tissue filling agent with anesthetic injecta before use Download PDFInfo
- Publication number
- CN102805882B CN102805882B CN201210309684.4A CN201210309684A CN102805882B CN 102805882 B CN102805882 B CN 102805882B CN 201210309684 A CN201210309684 A CN 201210309684A CN 102805882 B CN102805882 B CN 102805882B
- Authority
- CN
- China
- Prior art keywords
- syringe
- fix liquid
- soft tissue
- volume
- injects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000945 filler Substances 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 49
- 210000004872 soft tissue Anatomy 0.000 title claims abstract description 42
- 238000002156 mixing Methods 0.000 title abstract description 8
- 230000003444 anaesthetic effect Effects 0.000 title description 3
- 239000007924 injection Substances 0.000 claims abstract description 51
- 238000002347 injection Methods 0.000 claims abstract description 51
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 94
- 229940090044 injection Drugs 0.000 claims description 48
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 12
- 229960004194 lidocaine Drugs 0.000 claims description 12
- 229940071643 prefilled syringe Drugs 0.000 claims description 11
- -1 ovocaine Chemical compound 0.000 claims description 8
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 4
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 4
- 229960003150 bupivacaine Drugs 0.000 claims description 4
- 229960003976 etidocaine Drugs 0.000 claims description 4
- SIEYLFHKZGLBNX-NTISSMGPSA-N levobupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-NTISSMGPSA-N 0.000 claims description 4
- 229960002409 mepivacaine Drugs 0.000 claims description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 4
- 229960001807 prilocaine Drugs 0.000 claims description 4
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004919 procaine Drugs 0.000 claims description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 229940025300 lidocaine injection Drugs 0.000 claims description 3
- 230000036407 pain Effects 0.000 abstract description 19
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 7
- 229940035674 anesthetics Drugs 0.000 abstract description 6
- 239000003193 general anesthetic agent Substances 0.000 abstract description 6
- 229920002674 hyaluronan Polymers 0.000 abstract description 6
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 238000001556 precipitation Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000013112 stability test Methods 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 15
- 230000003796 beauty Effects 0.000 description 9
- 230000003533 narcotic effect Effects 0.000 description 9
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 6
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010073753 Fear of injection Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Abstract
The invention discloses a method for mixing soft tissue filling agent with anesthetics injecta before use. The method comprises the following steps of: injecting anesthetics injecta into a prefilling injector filled with soft tissue filling agent by a microsyringe for multiple times, after the anesthetics injecta is injected, stewing for a short time, and then performing even mixing. According to the method, the pain caused by the cosmetic injection can be avoided, the method is high in operability, and is low in technical requirements on operating personnel, and the anesthetics injecta and the soft tissue filling agent can be evenly mixed with each other conveniently and quickly. Compared with the existing method for preparing the preparation by directly adding the anesthetics into hyaluronic acid gel, the method has the advantage of not needing the compatibility test, the stability test and even the clinic test of two drugs under the condition of high-temperature sterilization, so that the method is low in cost. Furthermore, after the mixing is carried out by the method, the soft tissue filling agent is free from the chemical reaction phenomena such as degradation, precipitation, turbidness and the like, so that the method is safe.
Description
Technical field
The present invention relates to a kind ofly by two kinds of methods that medicine mixes use before use of Immiscible, be specifically related to a kind of method that soft tissue filler mixes with fix liquid before use.
Background technology
Injection beauty treatment is a kind of of non-operating shaping beauty treatment, utilize the method for injection that biomaterial or synthetic biocompatible materials are injected into skin corium or subcutaneous, by the different mechanism of action, reach a large class plastic operation method that reduces skinfold or plastotype.Injection beauty implement has without advantages such as operation, painful little, few side effects, instant effects, and the market demand constantly expands.
Along with injection beautifying technique is more and more flourishing, injection beauty treatment crowd also more and more grows.In exploitation injection cosmetics, injecting self experiencing of beauty treatment person also becomes the factor of doctor and manufacturer's consideration gradually, when Injection of Hyaluronic Acid gel filling agent product, the puzzlement that the distending pain that after pain during injection and injection, filler causes in vivo and sense of discomfort become numerous beauty treatment persons.In order to reduce or reduce patient's misery, conventionally the person of being injected is carried out to anaesthetic treatment, there is at present following anesthesia:
1, topical anesthesia: the anesthesia unguentum such as lignocaine are applied to skin to be injected place, disinfect in alcohol after 30-60 min.The method can only be eliminated the pain causing in injection process, and the distending pain that filler is caused is invalid.
2, anesthesia injection: injecting anesthetic remover liquid injection, the method also only can be eliminated the pain causing in injection fillers agent process, and the distending pain that filler is caused is invalid, and injection lignocaine also can bring pain.
3, anesthetis is mixed and in hyaluronic acid, make compositions, thereby thoroughly solve injection pain and filler swelling pain problem, had at present a lot of producers that the anesthetis such as lignocaine are joined in filler, Patents has CN200980139162.0(to comprise narcotic hyaluronic acid-based gel), CN200980139163.5(comprises narcotic hyaluronic acid-based gel), CN200880115067.2(anesthetics compositions, preparation and using method).In implant, directly admixture anesthetis can be removed the pain of injection and the pain of the rear swelling of filling simultaneously, removes and is administered to the pain that patient brings.
Summary of the invention
The present invention is directed to above deficiency, a kind of method that provides soft tissue filler to mix with fix liquid before use, the method can be before injection by fix liquid and soft tissue filler mix homogeneously in the short period of time, thereby can eliminate while injecting and all pain of bringing after injection simultaneously, remove patient's pain, and the method is convenient, fast, without by special equipment and condition, can not increase the financial burden of user.
The present invention is achieved by the following measures:
A kind of method that soft tissue filler mixes with fix liquid before use, described soft tissue filler includes but not limited to hyalomitome acids soft tissue filler (hyalomitome acids comprises hyaluronic acid or its salt), and described fix liquid is one or more in lignocaine, procaine, ovocaine, prilocaine, bupivacaine, mepivacaine, Carbocainum, etidocaine and chirocaine injection; Fix liquid is injected to soft tissue filler several times, and fix liquid injects the diverse location of soft tissue filler at every turn.Standing a period of time of gained mixture is mix homogeneously, and this time is about 5-10 min.
Concrete, mixed method of the present invention comprises the following steps:
(1) get in the prefilled syringe that soft tissue filler is housed (be called for short syringe, lower with) of sterilizing, by moving after the catch bar of syringe, make to vacate in syringe the space that holds fix liquid;
(2) with the microsyringe of sterilizing, extract fix liquid, standby;
(3) soft tissue filler volume is designated as to V1, fix liquid is divided into X part, divide and inject syringe X time, method for implanting is as follows: first, the syringe needle of microsyringe is penetrated until the bottom of soft tissue filler from the head of syringe, to the fix liquid that injects a volume in syringe, then by the syringe needle of microsyringe, to injector cephalad direction, (be also injector head direction, retreat the distance of V1/X volume down together), again to the fix liquid that injects a volume in syringe, continuation retreats the syringe needle of microsyringe the distance of V1/X volume to injector cephalad direction, and then to the fix liquid that injects a volume in syringe, the step that so microsyringe retreats and injects repeatedly, until fix liquid all injects syringe,
(4) fix liquid all injects after syringe, by syringe horizontal positioned, places 5-10 min and can use under aseptic, normal temperature environment.
In above-mentioned mixed method, fix liquid divides injection syringe 5-10 time, the time that more fix of the number of times liquid dividing is mixed homogeneously with filler is shorter, also there is no too large necessity, so preferably divide and inject syringes 10 times but the each volume injecting of fix liquid is too small.
In above-mentioned mixed method, preferably fix liquid is equally divided into X part, the volume of so each injection syringe is identical.After fix liquid is divided equally, do not divide equally and mix shortly than it with the incorporation time of filler, general 5-10 min is mix homogeneously.
The present invention's anesthetis, narcotic concentration, narcotic kind used all belongs to prior art, and those skilled in the art can obtain from prior art.For example, the volume ratio of fix liquid and soft tissue filler adopts the general proportionate relationship of using in prior art, general volume ratio is 1:5 ~ 1:20, in fix liquid, narcotic concentration (w/w) is generally 0.05%～0.5%, fix liquid used can be one or more in lignocaine, procaine, ovocaine, prilocaine, bupivacaine, mepivacaine, Carbocainum, etidocaine and chirocaine injection, preferably lidocaine injection.
The pain causing during for fear of injection beauty treatment, the invention provides a kind of method that soft tissue filler mixes with fix liquid before use, this method is workable, to operator technical require low, can be easy, quickly fix liquid is mixed homogeneously with soft tissue filler, directly add the method for making preparation in hyaluronic acid derivatives to compare fix liquid with disclosed now, needn't do the Experiment of Compatibility of two kinds of medicines under high temperature sterilize condition, stability experiment is clinical trial even, cost is low and adopt the rear soft tissue filler of this method mixing can not degrade, also there will not be precipitation, the muddy chemical reaction phenomenon that waits, it is safe method.
Accompanying drawing explanation
Fig. 1 is the present invention mixes soft tissue filler before use schematic diagram with fix liquid.
In figure, 1, prefilled syringe, 2, catch bar, 3, soft tissue filler, 4, vacant position, 5, microsyringe, 6, fix liquid, 7, syringe needle.
The specific embodiment
The front soft tissue filler of the applicable beauty treatment injection of method of the present invention mixes with fix liquid, below in conjunction with Fig. 1, mixed method of the present invention is carried out to detailed explanation.
As shown in Figure 1, prefilled syringe 1(is called for short syringe, down together), soft tissue filler is housed and (is called for short filler, lower same) 3, fix liquid 6 is housed in microsyringe 5, this fix liquid, in strict accordance with the consumption metering of filler, reaches when injection patient is carried out to the fully object of anesthesia.Fix liquid is injected to filler several times, fix liquid injects the diverse location of soft tissue filler at every turn, fix liquid is dispersed in the diverse location of filler, can mix homogeneously with filler faster like this, the liquid of fix simultaneously adds several times, has prevented from once adding problems such as causing bubble to occur.
Lower mask body is introduced mixed method of the present invention, in order to express easily, filler volume is designated as to V1, and the volume of fix liquid is designated as to V2, and fix liquid injects syringe several times, and the injection number of times of fix liquid is designated as to X.Before mixing starts, first by the catch bar of syringe 12 slow astern segment distances, make injector head vacate a part of vacant position 4, so that hold the volume of fix liquid, the volume of vacant position preferably equates or is slightly larger than the volume of anesthesia liquid with the volume of fix liquid, on syringe, with scale, can accurately retreat certain distance according to scale above.After moving after catch bar, the syringe needle of microsyringe 7 is penetrated until the bottom of soft tissue filler (being the end position of catch bar) from the head of syringe.Fix liquid divides injection syringe X time, therefore fix liquid cumulative volume is divided into X part, each portion that injects X part, therefore preferably fix liquid is divided into X part, each volume injecting is preferably V2/X, on microsyringe, with scale, during injection, according to scale, can inject accurately the fix liquid of setting volume.
Mixed method of the present invention is not by the disposable injection implant of fix liquid, is difficult to like this mix homogeneously, and easily produces the difficult injection of bubble.Key problem in technology of the present invention is that fix liquid is divided into different umbers, filler is also divided into same umber, every part of fix liquid is injected respectively to every part of soft tissue filler that is arranged in diverse location, fix liquid and filler can be mixed evenly fast, and be difficult for producing bubble.
The committed step of mixed method of the present invention below: the syringe needle of microsyringe is inserted to behind the bottom of soft tissue filler, in syringe, inject the fix liquid that X part is a (the preferably fix liquid of V2/X volume), then the syringe needle of microsyringe is retreated to the distance of V1/X volume to injector head position, again to the fix liquid liquid (the preferably fix liquid of V2/X volume) that injects a volume in syringe, continuation retreats the syringe needle of microsyringe the distance of V1/X volume to injector head position, and then to the fix liquid liquid (the preferably fix liquid of V2/X volume) that injects a volume in syringe, the step that so microsyringe retreats and injects repeatedly, until fix liquid all injects syringe.Fix liquid all injects after syringe, by syringe under aseptic, normal temperature environment, horizontal positioned, fix liquid is further mixed naturally with filler, through lot of experimental data, add up, after standing 5-10 min, fix liquid is to mix homogeneously with filler, after mix homogeneously, in injector head, set up aseptic syringe needle, can inject use.
In theory, the number of times that fix liquid injects is more, and the umber that filler is divided into is also more, mix quicker, but consider and operability generally fix liquid be divided into 5-10 part, be divided into 5-10 time and inject syringe, be i.e. X=5-10, preferably X=10.
Generally, beauty industry fix liquid used is including but not limited to lignocaine, procaine, ovocaine, prilocaine, bupivacaine, mepivacaine, Carbocainum, etidocaine, chirocaine injection etc., fix liquid of the present invention can be a kind of in these, also can be the mixture of the multiple composition in them, preferred lidocaine injection.
General, in fix liquid, narcotic concentration (w/w) is 0.05%～0.5%, can in market now, be chosen in the product of this concentration range, according to required narcotic amount, fix liquid concentration is large, the volume using is just relatively smaller, fix liquid concentration is little, the volume using is just larger, when the present invention mixes, anesthetis used and bulking of soft tissue adopts the conventional consumption in this area with magnitude relation, be generally fix liquid: the volume ratio of soft tissue filler is 1:5 ~ 1:20, in the specific implementation, the volume ratio that can select fix liquid and soft tissue filler is the arbitrary value in scope for this reason, 1:5 for example, 1:10, 1:15, 1:20 etc.According to narcotic consumption, can select the fix liquid of suitable concn, suitable volumes to mix with implant.And can determine according to the volume size of fix liquid the parameters such as injection number of times of fix liquid.
Lignocaine take below as example, enumerate preferred embodiment of the present invention, soft tissue filler commodity used profit by name hundred face, general injection by name is modified hyaluronic acid sodium gel (abbreviation gel), concentration is 1ml:20mg, by China prosperous Fu Ruida biological medicine company limited, is produced; Lignocaine used is the lidocaine hydrochloride injection of concentration (w/w) 0.2%, by Shangdong Hualu Pharmaceutical Co., Ltd., is produced.
Embodiment
Get the prefilled syringe that injection hyaluronic acid sodium gel is housed, 1 ml gel is housed in prefilled syringe body, with microsyringe, extract the lidocaine hydrochloride injection that 0.1 ml concentration (w/w) is 0.2%.The catch bar of prefilled syringe is retreated to 0.1 ml left and right, the syringe needle of microsyringe is inserted into the bottom of gel, inject 10 μ l lidocaine hydrochloride injections, then the syringe needle of microsyringe is retreated to the distance of 0.1 ml to prefilled syringe cephalad direction, 10 μ l lidocaine hydrochloride injections reinject, the operation that so microsyringe retreated and injected lidocaine hydrochloride injection repeatedly, until lidocaine hydrochloride all injects prefilled syringe, injecting number of times is 10 times.
After mixing, by prefilled syringe horizontal positioned, standing 5-10 min under aseptic, normal temperature environment, occurs without phenomenons such as muddiness, precipitations, places after 12 h, and lamp inspection observation, with dosing liquid product there was no significant difference not.
This method is mixed to the fix liquid of gained and the mixture of filler carries out clinical trial among a small circle, test number is 8 people, male 4 people, and women 4 people, the age, the mean age was 38.4 years old between 20-50 year, all experimenter's healths are all healthy.Before injection, adopt the inventive method in advance lignocaine to be sneaked into injection and modify in hyaluronic acid sodium gel, standing 10 min, then set up aseptic syringe needle in injector head, injection is modified to hyaluronic acid sodium gel and inject experimenter's nasolabial fold wrinkle.One side is modified hyaluronic acid sodium gel by the injection of mixing lignocaine, and opposite side is not modified hyaluronic acid sodium gel containing narcotic injection with conventional.Experimenter self is felt as injection: compares with the product of Caledonia caine not, and the pain while adding the product of lignocaine can significantly alleviate injection and the distending pain after injection etc., and after injection, ametaboly reaction or other untoward reaction occur.Meanwhile, experimenter's pain of Caledonia caine is light, has reduced the side reaction after injection.The explanation of this phenomenon, the inventive method can be by fix liquid and the abundant mix homogeneously of filler, and uses safety, and the pain of having exempted user has alleviated the fear of user, reduces postoperative rate of side effects.
Claims (6)
1. the method that soft tissue filler mixes with fix liquid before use, it is characterized by described soft tissue filler and include but not limited to hyalomitome acids soft tissue filler, described fix liquid is one or more in lignocaine, procaine, ovocaine, prilocaine, bupivacaine, mepivacaine, Carbocainum, etidocaine and chirocaine injection; Fix liquid is injected to soft tissue filler several times, and fix liquid injects the diverse location of soft tissue filler at every turn; Comprise the following steps:
(1) get the prefilled syringe that soft tissue filler is housed, by moving after the catch bar of prefilled syringe, make to vacate in syringe the space that holds fix liquid;
(2) with the microsyringe of sterilizing, extract fix liquid, standby;
(3) soft tissue filler volume is designated as to V1, fix liquid is divided into X part, divide and inject syringe X time, method for implanting is as follows: first, the syringe needle of microsyringe is penetrated until the bottom of soft tissue filler from the head of syringe, to the fix liquid that injects a volume in syringe, then the syringe needle of microsyringe is retreated to the distance of V1/X volume to injector cephalad direction, again to the fix liquid that injects a volume in syringe, continuation retreats the syringe needle of microsyringe the distance of V1/X volume to injector cephalad direction, and then to the fix liquid that injects a volume in syringe, the step that so microsyringe retreats and injects repeatedly, until fix liquid all injects syringe,
(4) fix liquid all injects after syringe, by syringe horizontal positioned, places 5-10 min and can use under aseptic, normal temperature environment.
2. method according to claim 1, is characterized in that: fix liquid divides injection syringe 5-10 time.
3. method according to claim 2, is characterized in that: fix liquid divides injection syringe 10 times.
4. method according to claim 1, is characterized in that: fix liquid is divided into X part, and the volume that at every turn injects syringe is identical.
5. method according to claim 1 and 2, is characterized in that: the volume ratio of fix liquid and soft tissue filler is 1:5 ~ 1:20.
6. method according to claim 1 and 2, is characterized in that: described fix liquid is lidocaine injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210309684.4A CN102805882B (en) | 2012-08-28 | 2012-08-28 | Method for mixing soft tissue filling agent with anesthetic injecta before use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210309684.4A CN102805882B (en) | 2012-08-28 | 2012-08-28 | Method for mixing soft tissue filling agent with anesthetic injecta before use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102805882A CN102805882A (en) | 2012-12-05 |
| CN102805882B true CN102805882B (en) | 2014-04-23 |
Family
ID=47229864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210309684.4A Active CN102805882B (en) | 2012-08-28 | 2012-08-28 | Method for mixing soft tissue filling agent with anesthetic injecta before use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102805882B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9421198B2 (en) * | 2013-07-30 | 2016-08-23 | Teoxane | Composition comprising hyaluronic acid and mepivacaine |
| FR3015290B1 (en) * | 2013-12-23 | 2017-01-13 | Lab Vivacy | HYALURONIC ACID COMPOSITIONS COMPRISING MEPIVACAINE |
| US10004824B2 (en) | 2015-05-11 | 2018-06-26 | Laboratoires Vivacy | Compositions comprising at least one polyol and at least one anesthetic |
| KR102091452B1 (en) * | 2017-12-19 | 2020-03-20 | 대화제약 주식회사 | Method for preparing prefilled syringe comprising local anesthetics and hyaluronic acid hydrogel |
| TWI731660B (en) * | 2020-04-24 | 2021-06-21 | 透策生技股份有限公司 | Processing method for accelerating the dispersion of injection-type fillers by means of pressurization |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172457A (en) * | 1977-10-06 | 1979-10-30 | American Hospital Supply Corporation | Plural component mixing system and method |
| US4254768A (en) * | 1979-09-14 | 1981-03-10 | Ty Perla J | Hypodermic syringe |
| US4743229A (en) * | 1986-09-29 | 1988-05-10 | Collagen Corporation | Collagen/mineral mixing device and method |
| US20050287180A1 (en) * | 2004-06-15 | 2005-12-29 | Chen Andrew X | Phospholipid compositions and methods for their preparation and use |
-
2012
- 2012-08-28 CN CN201210309684.4A patent/CN102805882B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102805882A (en) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102805882B (en) | Method for mixing soft tissue filling agent with anesthetic injecta before use | |
| Goldie et al. | Global consensus guidelines for the injection of diluted and hyperdiluted calcium hydroxylapatite for skin tightening | |
| Alam et al. | Injection technique in neurotoxins and fillers: indications, products, and outcomes | |
| US9468779B2 (en) | Viscoelastic gel for dermatological use | |
| Romagnoli et al. | Hyaluronic acid–based fillers: theory and practice | |
| BR112015031026B1 (en) | method for crosslinking hyaluronic acid or one of its salts or other biocompatible polymers; method for preparing an injectable hydrogel; hydrogel; kit and use | |
| CN105748315B (en) | A kind of composition for repairing skin barrier | |
| AU2014217942B2 (en) | Compositions and methods for pain relief without numbness | |
| WO1993002699A1 (en) | Use of collagen for the treatment of degenerative joint ailments | |
| Vedamurthy | Soft tissue augmentation-Use of hyaluronic acid as dermal filler | |
| CN106176758B (en) | A kind of externally-applied medicinal composition | |
| CN102641236B (en) | Expandable biological adhesive sustained and controlled release preparation for preventing and curing oral diseases and preparation method thereof | |
| CN110151687A (en) | A kind of stable chloraldurate solution and its preparation method and application | |
| CA2496121A1 (en) | Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy | |
| CN105031621B (en) | Recombinant human interferon alpha 2 b gel and preparation method thereof | |
| CN110433132B (en) | Tetrandrine nasal preparation for treating post-traumatic stress disorder | |
| CN102526112B (en) | Sustained-release pearl clear-sighted eye drops and preparation method thereof | |
| CN103301461A (en) | Long-acting injectable preparation, preparation method and application thereof | |
| WO2010138095A1 (en) | Medicinal agent | |
| Van Loghem | Use of calcium hydroxylapatite for augmentation of the labia majora and mons pubis | |
| CN106177970B (en) | Ropivacaine injection preparation and its preparation method and application | |
| CN107252490B (en) | A kind of local anaesthesia drug and preparation method thereof | |
| YUTSKOVSKAYA et al. | Neck and chest | |
| CN107441553B (en) | Preparation method of beauty implant | |
| Coimbra et al. | Injectable Poly-L-Lactic Acid for the Arms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING BLOOMAGE HYINC TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BLOOMAGE FREDA BIOPHARM CO., LTD. Effective date: 20140605 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 100022 CHAOYANG, BEIJING |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140605 Address after: 100022, Beijing, Chaoyang District, No. 6, No. 23, D, block 3, World Trade Center, Central Patentee after: BEIJING HUAXI HAIYU TECHNOLOGY CO.,LTD. Address before: Tianchen Avenue, Ji'nan hi tech Development Zone of Shandong Province, No. 678 250101 Patentee before: BLOOMAGE FREDA BIOPHARM Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20190724 Address after: 250101 high tech Zone, Shandong, Ji'nan Century Avenue, No. 3333 Patentee after: SHANDONG BLOOMAGE HYINC BIOPHARM Corp.,Ltd. Address before: 100022, Beijing, Chaoyang District, No. 6, No. 23, D, block 3, World Trade Center, Central Patentee before: BEIJING HUAXI HAIYU TECHNOLOGY CO.,LTD. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230620 Address after: Tianchen Avenue, Ji'nan hi tech Development Zone of Shandong Province, No. 678 250101 Patentee after: BLOOMAGE BIOTECH Co.,Ltd. Address before: 250101 No. 3333, Century Avenue, high tech Zone, Ji'nan, Shandong Patentee before: SHANDONG BLOOMAGE HYINC BIOPHARM Corp.,Ltd. |
|
| TR01 | Transfer of patent right |